Two new papers make it abundantly clear that treating the disease of
#obesity helps to improve one of its important symptoms – heart failure. Take note of these
#HFpEF papers on
#semaglutide in NEJM and The Lancet.
https://conscienhealth.org/2024/04/confirming-the-benefit-of-semaglutide-in-heart-failure/
Confirming the Benefit of Semaglutide in Heart Failure - ConscienHealth
Two new publications make it abundantly clear that treating obesity with semaglutide has important benefits for patients with heart failure.
ConscienHealth
Version 4 der Nationalen VersorgungsLeitlinie Chronische Herzinsuffizienz veröffentlicht
Friday, we learned from Mikhail Kosiborod et al that
#semaglutide helps patients with
#HFpEF and
#obesity. Today in Nature Medicine we learn why. It's all about providing real, effective obesity treatment.
https://conscienhealth.org/2023/08/hfpef-actually-treating-obesity-makes-the-difference/
HFpEF: Actually Treating Obesity Makes the Difference - ConscienHealth
Actually treating obesity – rather than merely telling a patient to lose weight – makes a big difference in clinical outcomes for HFpEF.
ConscienHealthWow!
In obesity and a type of
#HeartFailure called
#HFpEF,
#semaglutide reduces symptoms, restores physical function, and cuts serious adverse events in half. New study in NEJM by Mikhail Kosiborod et al.
https://conscienhealth.org/2023/08/impressive-semaglutide-outcomes-in-obesity-and-heart-failure/
Impressive Semaglutide Outcomes in Obesity and Heart Failure - ConscienHealth
In NEJM yesterday, an impressive RCT of semaglutide in patients with obesity and heart failure shows the value of treating obesity.
ConscienHealth#Sirt6 control of #EndothelialCell #FattyAcid transport links #Diabetes microvascular dysfunction with #HeartFailurewithPreservedEjectionFraction #HFpEF
EC Sirt6->
⏬H3K9ac PPARγ promoter
⏬CD36,FABP4/5
⏬🐭 Heart Lipid
Dr. Zheng Gen Jin lab Circ Res 2022
https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.121.318988

SIRT6 Mitigates Heart Failure With Preserved Ejection Fraction in Diabetes
Background: Heart failure with preserved ejection fraction (HFpEF) is a growing health problem without effective therapies. Epidemiological studies indicate that diabetes is a strong risk factor for
Circulation Research